Stoke Therapeutics, Inc. Increase (Decrease) in Deferred Revenue
Stoke Therapeutics, Inc. (STOK) reported Increase (Decrease) in Deferred Revenue of -$4.69 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2026-08-03
- Stoke Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2026-06-30 was -$2.49M.
- Stoke Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2026-03-31 was -$2.19M, a 123.26% decline year-over-year.
- Stoke Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2025-12-31 was $4.54M.
- Stoke Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2025-09-30 was -$4.06M.
- Stoke Therapeutics, Inc. increase (decrease) in deferred revenue for fiscal 2025 was -$130.00K.
- Stoke Therapeutics, Inc. increase (decrease) in deferred revenue for fiscal 2024 was -$29.39M.
- Stoke Therapeutics, Inc. increase (decrease) in deferred revenue for fiscal 2023 was -$3.35M, a 106.48% decline from fiscal 2022.
- Stoke Therapeutics, Inc. increase (decrease) in deferred revenue for fiscal 2022 was $51.74M.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$2.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | -$4.69M 10-Q · filed 2026-08-03 | -$146.00K derived: sum of 3 quarters · filed 2026-08-03 | -$4.21M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | -$2.19M 10-Q · filed 2026-05-07 | $2.35M derived: sum of 2 quarters · filed 2026-05-07 | -$1.71M derived: sum of 3 quarters · filed 2026-05-07 | -$11.75M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $4.54M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $481.00K derived: sum of 2 quarters · filed 2026-03-16 | -$9.56M derived: sum of 3 quarters · filed 2026-08-03 | -$130.00K 10-K · filed 2026-03-16 |
| 2025-09-30 | -$4.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$14.10M derived: sum of 2 quarters · filed 2026-08-03 | -$4.67M 10-Q · filed 2025-11-04 | -$25.58M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | -$10.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | -$611.00K 10-Q · filed 2026-08-03 | -$21.52M derived: sum of 3 quarters · filed 2026-08-03 | -$24.62M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $9.43M 10-Q · filed 2026-05-07 | -$11.48M derived: sum of 2 quarters · filed 2026-05-07 | -$14.58M derived: sum of 3 quarters · filed 2026-05-07 | -$17.54M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$20.91M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$24.01M derived: sum of 2 quarters · filed 2026-03-16 | -$26.97M derived: sum of 3 quarters · filed 2026-03-16 | -$29.39M 10-K · filed 2026-03-16 |
| 2024-09-30 | -$3.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$6.06M derived: sum of 2 quarters · filed 2025-11-04 | -$8.48M 10-Q · filed 2025-11-04 | -$9.56M derived: sum of 4 quarters · filed 2025-11-04 |
| 2024-06-30 | -$2.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$5.39M 10-Q · filed 2025-08-12 | -$6.46M derived: sum of 3 quarters · filed 2025-08-12 | -$8.32M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$2.42M 10-Q · filed 2025-05-13 | -$3.50M derived: sum of 2 quarters · filed 2025-05-13 | -$5.36M derived: sum of 3 quarters · filed 2025-05-13 | -$1.63M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$1.08M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | -$2.93M derived: sum of 2 quarters · filed 2025-03-18 | $789.00K derived: sum of 3 quarters · filed 2025-03-18 | -$3.35M 10-K · filed 2025-03-18 |
| 2023-09-30 | -$1.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $1.87M derived: sum of 2 quarters · filed 2024-11-05 | -$2.27M 10-Q · filed 2024-11-05 | -$4.45M derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | $3.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | -$418.00K 10-Q · filed 2024-08-07 | -$2.60M derived: sum of 3 quarters · filed 2024-08-07 | -$4.53M derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | -$4.14M 10-Q · filed 2024-05-06 | -$6.32M derived: sum of 2 quarters · filed 2024-05-06 | -$8.25M derived: sum of 3 quarters · filed 2024-05-06 | -$10.42M derived: sum of 4 quarters · filed 2024-05-06 |
| 2022-12-31 | -$2.18M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | -$4.11M derived: sum of 2 quarters · filed 2024-03-25 | -$6.28M derived: sum of 3 quarters · filed 2024-03-25 | $51.74M 10-K · filed 2024-03-25 |
| 2022-09-30 | -$1.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$4.10M derived: sum of 2 quarters · filed 2023-11-07 | $53.92M 10-Q · filed 2023-11-07 | |
| 2022-06-30 | -$2.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $55.84M 10-Q · filed 2023-08-07 | ||
| 2022-03-31 | $58.01M 10-Q · filed 2023-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |